The company operates as a pharmaceutical distributor and wholesaler in India, sourcing medicines and healthcare products from manufacturers to supply retail pharmacies and medical stores.
The company lacks a durable moat, as evidenced by razor-thin net margins of approximately 1.1% and a return on capital (7.5%) that likely fails to exceed its cost of capital. While they claim a strong distribution network, the business is a commodity middleman service with no proprietary brands or significant switching costs, corroborated by the high level of competition and low pricing power.
Capital has been primarily directed toward working capital and acquiring majority stakes in related partnership firms like Ahmedabad Medical Corporation. The negative cash conversion and high debt-to-equity ratio of 1.75 suggest that growth is being funded by leverage rather than internal cash flow, which is unsustainable given the low interest coverage of 1.33.
The company collapsed under the weight of its own leverage as interest rates rose while its razor-thin margins remained stagnant. The negative cash conversion cycle eventually triggered a liquidity crisis, as the business could no longer borrow to fund its bloated receivables. The discrepancy between bank filings and audited accounts, previously ignored, culminated in a loss of credit facilities, while the heavy reliance on related-party transactions drained what little equity remained into promoter-controlled entities.
RichFakir rates Mono Pharmacare Ltd's business quality as poor — 14/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Mono Pharmacare Ltd is trading about 9% below our estimate of fair value; we rate its price fair. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Mono Pharmacare Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Mono Pharmacare Ltd's fair value is about ₹10 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →